Immatics N.V. (NASDAQ:IMTX - Get Free Report) insider Rainer Kramer sold 22,868 shares of the firm's stock in a transaction that occurred on Thursday, November 19th. The shares were sold at an average price of $6.06, for a total value of $138,580.08. Following the transaction, the insider directly owned 22,868 shares of the company's stock, valued at approximately $138,580.08. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Immatics Trading Down 3.1%
NASDAQ:IMTX traded down $0.19 during trading hours on Friday, reaching $5.76. 744,788 shares of the company traded hands, compared to its average volume of 603,261. The business's 50-day moving average price is $7.46 and its two-hundred day moving average price is $9.34. The stock has a market capitalization of $787.88 million, a P/E ratio of -2.96 and a beta of 1.38. Immatics N.V. has a 1 year low of $5.72 and a 1 year high of $12.41.
Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.07). Immatics had a negative return on equity of 52.54% and a negative net margin of 533.26%. The company had revenue of $7.84 million during the quarter, compared to the consensus estimate of $12.18 million. As a group, equities analysts anticipate that Immatics N.V. will post -2.03 EPS for the current year.
Institutional Trading of Immatics
Several institutional investors have recently added to or reduced their stakes in IMTX. Goldman Sachs Group Inc. raised its stake in shares of Immatics by 3.6% in the third quarter. Goldman Sachs Group Inc. now owns 398,004 shares of the company's stock worth $3,494,000 after purchasing an additional 13,833 shares during the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of Immatics during the third quarter valued at $6,058,000. Marshall Wace LLP bought a new stake in Immatics in the 3rd quarter worth about $3,685,000. Aberdeen Group plc increased its holdings in Immatics by 89.0% in the 3rd quarter. Aberdeen Group plc now owns 1,235,460 shares of the company's stock worth $10,847,000 after buying an additional 581,856 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in Immatics by 46.2% in the 3rd quarter. Alps Advisors Inc. now owns 198,239 shares of the company's stock worth $1,741,000 after buying an additional 62,640 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on IMTX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immatics in a research note on Friday, September 18th. Jefferies Financial Group restated a "buy" rating on shares of Immatics in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Immatics in a report on Tuesday, October 13th. They issued a "buy" rating and a $15.00 target price for the company. Mizuho set a $21.00 target price on shares of Immatics in a report on Thursday, October 29th. Finally, Wall Street Zen downgraded shares of Immatics from a "hold" rating to a "sell" rating in a research note on Saturday, October 31st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.
Read Our Latest Stock Report on Immatics
About Immatics
(
Get Free Report)
Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient's T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.